Patent ID: 7615349
Filing Date: 2009-11-10
Classification: C12Q

Abstract:
1. A method of evaluating a melanoma from a patient, the method comprising: determining mRNA levels of five or more genes selected from the group consisting of: tripartite motif-containing 51 (TRIM51) (SEQ ID NO:1); Glycophorin C (Gerbich blood group) (GYPC) (SEQ ID NO:2); SRY (sex determining region Y)-box 5 (SOX5) (SEQ ID NO:3); kinesin family member C1 (KIFC1) (SEQ ID NO:4); SEC22 vesicle trafficking protein-like 3 ( comparing said mRNA levels to a set of reference levels that represent levels of the mRNAs in a sample comprising cells from a non-metastatic melanoma, wherein an increase in expression of said five or more genes indicates an increased likelihood that the melanoma is a metastatic melanoma.